absk061
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2022 (NCT05244551)
Timeline
Indications
Mechanism of action
- Fibroblast growth factor receptor 2ANTAGONIST
FGFR2 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07297875 | Phase 1/Phase 2 (Phase 2) | Dec 10, 2025 | Abbisko Therapeutics Co, Ltd |
| NCT07007546 | Phase 1 | May 17, 2025 | Abbisko Therapeutics Co, Ltd |
| NCT06632262 | Phase 2 | Nov 13, 2024 | Abbisko Therapeutics Co, Ltd, Fudan University |
| NCT05244551 | Phase 1 | Jun 30, 2022 | Abbisko Therapeutics Co, Ltd |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abbisko Therapeutics Co, Ltd | For profit | 4 | 4 | 2 | 2022 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1